UNICREDIT BANK/CALL/AMGEN/350/0.1/19.06.24 | Market Closed - BOERSE MUENCHEN 15:40:12 2024-05-31 EDT | ||
| 0.001 EUR | -.--% |
|
| 3 months | -97.30% | ||
| 6 months | -99.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.001 | -.--% |
| 24-05-30 | 0.001 | -.--% |
| 24-05-29 | 0.001 | -.--% |
| 24-05-28 | 0.001 | -.--% |
| 24-05-27 | 0.001 | -50.00% |
Real-time BOERSE MUENCHEN
Last update May 31, 2024 at 03:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3JAG |
| ISIN | DE000HC3JAG0 |
| Date issued | 2023-01-26 |
| Strike | 350 $ |
| Maturity | 2024-06-19 (17 Days) |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.04 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant
